1. Tumor reversion and embryo morphogenetic factors
- Author
-
Andrea Fuso, Cinzia Marchese, Andrea Pensotti, Sara Proietti, Andrea Nicolini, Mariano Bizzarri, and Alessandra Cucina
- Subjects
0301 basic medicine ,Cancer Research ,Gene regulatory network ,Biology ,Epigenesis, Genetic ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms ,Tumor Microenvironment ,Humans ,Cellular Reprogramming Techniques ,Epigenetics ,Cytoskeleton ,Wnt signaling pathway ,Morphogenetic field ,Cellular Reprogramming ,Chromatin Assembly and Disassembly ,Phenotype ,Chromatin ,Cell biology ,DNA Demethylation ,Cell Transformation, Neoplastic ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cancer cell ,Reprogramming - Abstract
Several studies have shown that cancer cells can be "phenotypically reversed", thus achieving a "tumor reversion", by losing malignant hallmarks as migrating and invasive capabilities. These findings suggest that genome activity can switch to assume a different functional configuration, i.e. a different Gene Regulatory Network pattern. Indeed, once "destabilized", cancer cells enter into a critical transition phase that can be adequately "oriented" by yet unidentified morphogenetic factors - acting on both cells and their microenvironment - that trigger an orchestrated array of structural and epigenetic changes. Such process can bypass genetic abnormalities, through rerouting cells toward a benign phenotype. Oocytes and embryonic tissues, obtained by animals and humans, display such "reprogramming" capability, as a number of yet scarcely identified embryo-derived factors can revert the malignant phenotype of several types of tumors. Mechanisms involved in the reversion process include the modification of cell-microenvironment cross talk (mostly through cytoskeleton reshaping), chromatin opening, demethylation, and epigenetic changes, modulation of biochemical pathways, comprising TCTP-p53, PI3K-AKT, FGF, Wnt, and TGF-β-dependent cascades. Results herein discussed promise to open new perspectives not only in the comprehension of cancer biology but also toward different therapeutic options, as suggested by a few preliminary clinical studies.
- Published
- 2022